{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:20Z","timestamp":1790788700919,"version":"4.1.0"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["RIA2017MC-2025"],"award-info":[{"award-number":["RIA2017MC-2025"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["91617140"],"award-info":[{"award-number":["91617140"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-01251"],"award-info":[{"award-number":["2022-01251"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria.<\/jats:p>","DOI":"10.1093\/jac\/dkad260","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:25:23Z","timestamp":1693229123000},"page":"2406-2418","source":"Crossref","is-referenced-by-count":30,"title":["Pyronaridine: a review of its clinical pharmacology in the treatment of malaria"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0402-8807","authenticated-orcid":false,"given":"Wan-Yu","family":"Chu","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmacology, Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P C","family":"Dorlo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology, Netherlands Cancer Institute , Amsterdam , The Netherlands"},{"name":"Department of Pharmacy, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"2023100302092039600_dkad260-B1","first-page":"118","article-title":"Synthesis of new antimalarial drug pyronaridine and its analogues","volume":"17","author":"Zheng","year":"1982","journal-title":"Acta Pharm Sin"},{"key":"2023100302092039600_dkad260-B2","first-page":"736","article-title":"Synthesis of 7351, a new antimalarial drug [author\u2019s translation]","volume":"14","author":"Zheng","year":"1979","journal-title":"Acta Pharm Sin"},{"key":"2023100302092039600_dkad260-B3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0764-4469(98)80009-7","article-title":"Impact of chloroquine resistance on malaria mortality","volume":"321","author":"Trape","year":"1998","journal-title":"C R Acad Sci III"},{"key":"2023100302092039600_dkad260-B4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(96)91548-2","article-title":"Pyronaridine: a promising drug for Africa?","volume":"347","author":"Winstanley","year":"1996","journal-title":"Lancet"},{"key":"2023100302092039600_dkad260-B5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(96)91558-5","article-title":"Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa","volume":"347","author":"Ringwald","year":"1996","journal-title":"Lancet"},{"key":"2023100302092039600_dkad260-B6","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/513942","article-title":"Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children","volume":"26","author":"Ringwald","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2023100302092039600_dkad260-B7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0163-7258(01)00140-1","article-title":"Artemisinin and its derivatives: an important new class of antimalarial agents","volume":"90","author":"Balint","year":"2001","journal-title":"Pharmacol Ther"},{"key":"2023100302092039600_dkad260-B8","author":"MMV (Medicinces for Malaria Venture)"},{"key":"2023100302092039600_dkad260-B9","author":"European Medicines Agency (EMA)"},{"key":"2023100302092039600_dkad260-B10","author":"European Medicines Agency (EMA)"},{"key":"2023100302092039600_dkad260-B11","volume-title":"WHO guidelines for the treatment of malaria","author":"World Health Organization","year":"2015","edition":"3rd ed"},{"key":"2023100302092039600_dkad260-B12","author":"World Health Organization"},{"key":"2023100302092039600_dkad260-B13","author":"World Health Organization"},{"key":"2023100302092039600_dkad260-B14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1874104501105010011","article-title":"Acridine and acridinones: old and new structures with antimalarial activity","volume":"5","author":"Vald\u00e9s","year":"2011","journal-title":"Open Med Chem J"},{"key":"2023100302092039600_dkad260-B15","author":"National Center for Biotechnology Information"},{"key":"2023100302092039600_dkad260-B16","first-page":"1","article-title":"Determination of the physicochemical properties of pyronaridine\u2014a new antimalarial drug","volume":"19","author":"Adegoke","year":"2006","journal-title":"Pak J Pharm Sci"},{"key":"2023100302092039600_dkad260-B17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007890","article-title":"Repurposing the antimalarial pyronaridine tetraphosphate to protect against ebola virus infection","volume":"13","author":"Lane","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2023100302092039600_dkad260-B18","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1128\/AAC.42.9.2410","article-title":"Effect of disposition of Mannich antimalarial agents on their pharmacology and toxicology","volume":"42","author":"Ruscoe","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-019-3075-5","article-title":"An in vitro toolbox to accelerate anti-malarial drug discovery and development","volume":"19","author":"Charman","year":"2020","journal-title":"Malar J"},{"key":"2023100302092039600_dkad260-B20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.103.056770","article-title":"Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs","volume":"308","author":"Siebert","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"2023100302092039600_dkad260-B21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.lfs.2006.11.008","article-title":"Antimalarial drugs inhibiting hemozoin (\u03b2-hematin) formation: a mechanistic update","volume":"80","author":"Kumar","year":"2007","journal-title":"Life Sci"},{"key":"2023100302092039600_dkad260-B22","doi-asserted-by":"crossref","DOI":"10.1002\/bip.23398","article-title":"Pyronaridine: an update of its pharmacological activities and mechanisms of action","volume":"112","author":"Bailly","year":"2021","journal-title":"Biopolymers"},{"key":"2023100302092039600_dkad260-B23","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2023100302092039600_dkad260-B24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fimmu.2014.00025","article-title":"Malarial pigment hemozoin and the innate inflammatory response","volume":"5","author":"Olivier","year":"2014","journal-title":"Front Immunol"},{"key":"2023100302092039600_dkad260-B25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1128\/AAC.00119-06","article-title":"Targeting of hematin by the antimalarial pyronaridine","volume":"50","author":"Auparakkitanon","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B26","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1128\/AAC.47.12.3708-3712.2003","article-title":"Antimalarial 9-anilinoacridine compounds directed at hematin","volume":"47","author":"Auparakkitanon","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/cb300454t","article-title":"Insights into the role of heme in the mechanism of action of antimalarials","volume":"8","author":"Combrinck","year":"2013","journal-title":"ACS Chem Biol"},{"key":"2023100302092039600_dkad260-B28","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1021\/bi9528098","article-title":"Interaction of a DNA-threading netropsin-amsacrine combilexin with DNA and chromatin","volume":"35","author":"Bourdouxhe-Housiaux","year":"1996","journal-title":"Biochemistry"},{"key":"2023100302092039600_dkad260-B29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/AAC.37.3.403","article-title":"Structure-activity relationships and modes of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro","volume":"37","author":"Chavalitshewinkoon","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1006\/bbrc.2000.2305","article-title":"Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum","volume":"269","author":"Auparakkitanon","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"2023100302092039600_dkad260-B31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpddr.2017.03.002","article-title":"Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum","volume":"7","author":"Kemirembe","year":"2017","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2023100302092039600_dkad260-B32","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa1007125","article-title":"Pyronaridine\u2013artesunate versus mefloquine plus artesunate for malaria","volume":"366","author":"Rueangweerayut","year":"2012","journal-title":"N Engl J Med"},{"key":"2023100302092039600_dkad260-B33","first-page":"619","article-title":"Antimalarial activity of concanamycin A alone and in combination with pyronaridine","volume":"37","author":"Auparakkitanon","year":"2006","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2023100302092039600_dkad260-B34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1128\/AAC.43.6.1525","article-title":"In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum","volume":"43","author":"Ringwald","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/42.3.333","article-title":"In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents","volume":"42","author":"Pradines","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"2023100302092039600_dkad260-B36","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1039\/C7TB00449D","article-title":"Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7\/ADR cells","volume":"5","author":"Zhu","year":"2017","journal-title":"J Mater Chem B"},{"key":"2023100302092039600_dkad260-B37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0035-9203(92)90414-8","article-title":"Studies on a new antimalarial compound: Pyronaridine","volume":"86","author":"Chang","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2023100302092039600_dkad260-B38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2049-9957-3-9","article-title":"Development of antimalarial drugs and their application in China: a historical review","volume":"3","author":"Chen","year":"2014","journal-title":"Infect Dis Poverty"},{"key":"2023100302092039600_dkad260-B39","first-page":"1","article-title":"Role of ADME\/PK in drug discovery, safety assessment, and clinical development","volume":"4\u20138","author":"White","year":"2017","journal-title":"Compr Med Chem III"},{"key":"2023100302092039600_dkad260-B40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-4347(96)00410-0","article-title":"Determination of pyronaridine in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies","volume":"690","author":"Jayaraman","year":"1997","journal-title":"J Chromatogr B Biomed Appl"},{"key":"2023100302092039600_dkad260-B41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jchromb.2005.06.034","article-title":"A new and simple solid-phase extraction method for LC determination of pyronaridine in human plasma","volume":"824","author":"Ramanathan","year":"2005","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"2023100302092039600_dkad260-B42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1570-0232(03)00591-9","article-title":"Liquid chromatographic determination of pyronaridine in human plasma and oral dosage form","volume":"795","author":"Babalola","year":"2003","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"2023100302092039600_dkad260-B43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jchromb.2009.02.006","article-title":"A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma","volume":"877","author":"Hodel","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2023100302092039600_dkad260-B44","first-page":"354","article-title":"[Spectrofluorometric determination of pyronaridine, an antimalarial]","volume":"7","author":"Feng","year":"1986","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"2023100302092039600_dkad260-B45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0378-4347(00)00512-0","article-title":"Improved assay method for the determination of pyronaridine in plasma and whole blood by high-performance liquid chromatography for application to clinical pharmacokinetic studies","volume":"752","author":"Chen","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"2023100302092039600_dkad260-B46","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00007691-200306000-00003","article-title":"Determination of pyronaridine in whole blood by automated solid phase extraction and high-performance liquid chromatography","volume":"25","author":"Blessborn","year":"2003","journal-title":"Ther Drug Monit"},{"key":"2023100302092039600_dkad260-B47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2007.06.018","article-title":"Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies","volume":"45","author":"Naik","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"2023100302092039600_dkad260-B48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jpba.2017.08.023","article-title":"Quantification of the antimalarial drug pyronaridine in whole blood using LC\u2013MS\/MS\u2014increased sensitivity resulting from reduced non-specific binding","volume":"146","author":"Blessborn","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"2023100302092039600_dkad260-B49","author":"European Medicines Agency (EMA)","year":"2012"},{"key":"2023100302092039600_dkad260-B50","first-page":"543","article-title":"Pharmacokinetics of pyronaridine in malaria patients","volume":"8","author":"Feng","year":"1987","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"2023100302092039600_dkad260-B51","author":"European Medicines Agency (EMA)","year":"2012"},{"key":"2023100302092039600_dkad260-B52","first-page":"629","article-title":"Distribution and excretion of 3H-pyronaridine in mice","volume":"23","author":"Feng","year":"1988","journal-title":"Acta Pharm Sin"},{"key":"2023100302092039600_dkad260-B53","first-page":"801","article-title":"[Pharmacokinetics of pyronaridine, an antimalarial in rabbits]","volume":"21","author":"Feng","year":"1986","journal-title":"Yao Xue Xue Bao"},{"key":"2023100302092039600_dkad260-B54","author":"Wattanavijitkul","year":"2010"},{"key":"2023100302092039600_dkad260-B55","first-page":"485","article-title":"Measuring pH of the Plasmodium falciparum digestive vacuole by flow cytometry","volume":"32","author":"Bakar","year":"2015","journal-title":"Trop Biomed"},{"key":"2023100302092039600_dkad260-B56","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1475-2875-11-270","article-title":"Review of pyronaridine anti-malarial properties and product characteristics","volume":"11","author":"Croft","year":"2012","journal-title":"Malar J"},{"key":"2023100302092039600_dkad260-B57","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/590707","article-title":"Absorption, distribution, excretion, and pharmacokinetics of C14-pyronaridine tetraphosphate in male and female sprague-dawley rats","volume":"2010","author":"Park","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"2023100302092039600_dkad260-B58","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1021\/jm030796n","article-title":"Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials","volume":"46","author":"O\u2019Neill","year":"2003","journal-title":"J Med Chem"},{"key":"2023100302092039600_dkad260-B59","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/jms.663","article-title":"In vitro and in vivo metabolism of pyronaridine characterized by low-energy collision-induced dissociation mass spectrometry with electrospray ionization","volume":"39","author":"Lee","year":"2004","journal-title":"J Mass Spectrom"},{"key":"2023100302092039600_dkad260-B60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13318-014-0182-0","article-title":"Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers","volume":"40","author":"Morris","year":"2015","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2023100302092039600_dkad260-B61","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1128\/AAC.02716-14","article-title":"Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol","volume":"58","author":"Morris","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1128\/AAC.03829-14","article-title":"Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects","volume":"59","author":"Jittamala","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B63","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4269\/ajtmh.2012.11-0558","article-title":"Drug-drug interaction analysis of pyronaridine\/artesunate and ritonavir in healthy volunteers","volume":"86","author":"Morris","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2023100302092039600_dkad260-B64","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1475-2875-8-304","article-title":"Population pharmacokinetics of artesunate and dihydroartemisinin following single-and multiple-dosing of oral artesunate in healthy subjects","volume":"8","author":"Tan","year":"2009","journal-title":"Malar J"},{"key":"2023100302092039600_dkad260-B65","author":"Methaneethorn","year":"2013"},{"key":"2023100302092039600_dkad260-B66","author":"Ayyoub","year":"2016"},{"key":"2023100302092039600_dkad260-B67","author":"Shin Poong Pharmaceuticals Co. Ltd","year":"2016"},{"key":"2023100302092039600_dkad260-B68","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1086\/591096","article-title":"Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon","volume":"198","author":"Ramharter","year":"2008","journal-title":"J Infect Dis"},{"key":"2023100302092039600_dkad260-B69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/1475-2875-11-364","article-title":"Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial","volume":"11","author":"Kayentao","year":"2012","journal-title":"Malar J"},{"key":"2023100302092039600_dkad260-B70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","article-title":"Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial","volume":"16","author":"Sagara","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023100302092039600_dkad260-B71","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.02004-15","article-title":"Population pharmacokinetics of pyronaridine in pediatric malaria patients","volume":"60","author":"Ayyoub","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4269\/ajtmh.2012.11-0817","article-title":"Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells","volume":"87","author":"Oga","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2023100302092039600_dkad260-B73","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00436-019-06210-3","article-title":"Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers","volume":"118","author":"Ariffin","year":"2019","journal-title":"Parasitol Res"},{"key":"2023100302092039600_dkad260-B74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-12-212","article-title":"The metabolism of primaquine to its active metabolite is dependent on CYP 2D6","volume":"12","author":"Pybus","year":"2013","journal-title":"Malar J"},{"key":"2023100302092039600_dkad260-B75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1473-3099(07)70021-X","article-title":"Epidemiology and burden of malaria in pregnancy","volume":"7","author":"Desai","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"2023100302092039600_dkad260-B76","first-page":"401","article-title":"[The embryotoxicity of a new antimalarial pyronaridine in rats]","volume":"17","author":"Ni","year":"1982","journal-title":"Yao Xue Xue Bao"},{"key":"2023100302092039600_dkad260-B77","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"2023100302092039600_dkad260-B78","author":"Anon"},{"key":"2023100302092039600_dkad260-B79","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.actatropica.2007.12.005","article-title":"Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo","volume":"105","author":"Vivas","year":"2008","journal-title":"Acta Trop"},{"key":"2023100302092039600_dkad260-B80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00394-18","article-title":"Superior pyronaridine single-dose pharmacodynamics compared to artesunate, chloroquine, and amodiaquine in a murine malaria luciferase model","volume":"62","author":"Okoth","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302092039600_dkad260-B81","first-page":"70","author":"Duparc","year":"2013"},{"key":"2023100302092039600_dkad260-B82","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","author":"Sagara","year":"2018","journal-title":"Lancet"},{"key":"2023100302092039600_dkad260-B83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003669","article-title":"Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study","volume":"18","author":"Tona Lutete","year":"2021","journal-title":"PLoS Med"},{"key":"2023100302092039600_dkad260-B84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12936-021-03593-6","article-title":"Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso","volume":"20","author":"Compaor\u00e9","year":"2021","journal-title":"Malar J"},{"key":"2023100302092039600_dkad260-B85","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/1475-2875-13-358","article-title":"Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali","volume":"13","author":"Sagara","year":"2014","journal-title":"Malar J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2406\/51743423\/dkad260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2406\/51743423\/dkad260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:10:16Z","timestamp":1696299016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/10\/2406\/7252659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":85,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,8,28]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad260","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,28]]}}}